Abiopharma

🔍 DENELSKY STEPHEN J (Director)

Company: HARVARD BIOSCIENCE INC (HBIO)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Acquired 10,000 shares of Common Stock at $4.87 per share (Direct)
  Date: 2026-03-17 | Code: P | equity_swap_involved: 0 | shares_owned_after: 21,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Includes (a) 10,000 shares of common stock purchased on March 17, 2026 and (b) 11,000 restricted stock units that fully vest on September 5, 2026.
• F2: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.